Irish biotech firm Élan has seen its shares plunge this morning after it revealed that a fourth patient taking its new multiple sclerosis drug Tysabri had contracted a fatal brain disease.
Whilst US stock markets have not yet opened for business, Athlone based Élan has suffered a 22% drop on the Irish Stock Exchange and a 21.5% drop on the London Stock Exchange. That means that so far today the firms market value has dropped by over €400mm to €1.9bn. The firm was once valued at over €20bn before the failure of Tysabri and an accounting investigation.
Élan was once one of Ireland's biggest business success stories. Élan still employs over 2,000 people in Ireland and reported revenues of $464.0 million in 2004.

Have an opinion on this story? Share it!
Share this: 






This page is archived, and is no longer publicly editable.
Got a correction? Add the template {{editprotected}} to the talk page along with your corrections, and it will be brought to the attention of the administrators.
Please note that due to our archival policy, we will not alter or update the content of articles that are archived, but will only accept requests to make grammatical and formatting corrections.
Note that some listed sources or external links may no longer be available online due to age.
Got a correction? Add the template {{editprotected}} to the talk page along with your corrections, and it will be brought to the attention of the administrators.
Please note that due to our archival policy, we will not alter or update the content of articles that are archived, but will only accept requests to make grammatical and formatting corrections.

Public domain
Public domain
false
false
Elan shares plunge as another patient dies